Table 4.
Characteristics of studies assessing the role of FS for the resection of DLGGs.
| Study | Design | Effectives | Main Conclusions |
|---|---|---|---|
| STUDIES ASSESSING RESECTION GUIDED BY FLUORESCEIN SODIUM | |||
| Chen, 2012 [79] |
Prospective, monocentric Dose: 15–20 mg/kg (WHO 2007) |
10 gliomas, including 4 (40%) grade 2 |
FS fluorescence positivity 3/4 (75%) grade 2. Contrast enhancement in all fluorescent DLGGs but not in the remaining one. |
| Schebesch, 2013 [82] |
Retrospective, monocentric Dose: 3–4 mg/kg (WHO 2007) |
26 gliomas, including 3 (11.5%) grade 2 |
FS fluorescence Helpful in 2/3 DLGGs. |
| Schebesch, 2018 [80] | Retrospective, monocentric, Dose: 5 mg/kg (WHO 2016) |
5 gliomas without contrast enhancement but with 18F FET uptake, including 1 (20%) grade 2 3 (60%) grade 3 |
FS fluorescence positivity 100% cases (diffuse or focal). |
| Xiang, 2018 [81] |
Retrospective, monocentric Dose: 5 mg/kg (WHO 2016) |
28 gliomas 5 (17.9%) grade 2 6 (21.4%) grade 3 17 (60.7%) grade 4 |
FS fluorescence positivity 0/5 (0%) grade 2. Significant decrease in Claudin-5 expression by endothelial cells in fluorescent gliomas. |
| TOTAL | Positive FS fluorescence | ||
| 13 DLGGs | 46% (6/13) DLGGs | ||
| 5 grade 3 gliomas without CE | 60% (3/5) grade 3 gliomas without CE | ||
CE = Contrast Enhancement.